Avisi Technologies
- Industry
- Medical Device
- Founded Year
- 2017
- Headquarters
- Redwood City, California, United States
- Employee Count
- 18
Key People
- Rui Jing Jiang - Founder, CEO, and Director
- Jeff Emery, PhD - Senior VP of R&D and Operations
- Vidhya Vilupuru, MS, OD, PhD - Vice President, Clinical Affairs
- Georgia Griggs, MSE - Principal Engineer, Site Head
- Catherine Mohr, MD, MSME - Director of the Board
- Gary Pruden - Director of the Board
- Paul Norris, JD - Director of the Board
- Justin Fukuyama, MS, MBA - Director of the Board
- Brandon Kao, MD - Founder
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises first-time entrepreneurs with over 10 years of experience in their respective fields.
The leadership team includes individuals with significant experience in research and development, clinical affairs, and engineering. For instance, Jeff Emery, PhD, has over 10 years of experience in R&D and operations, contributing to the company's strong foundation.
- Clinical Need
-
Aspect: Very Strong
Summary: Glaucoma is a leading cause of irreversible blindness, indicating a very strong clinical need for effective treatments.
Glaucoma affects millions worldwide and is the second leading cause of blindness. Current treatments are limited, highlighting the urgent need for innovative solutions like VisiPlate.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing players, but opportunities exist for innovative solutions.
The glaucoma treatment market includes established devices like the Ahmed Glaucoma Valve and the Baerveldt Implant. However, VisiPlate's nanotechnology offers a unique approach that could set it apart.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing nanotechnology-enabled implants presents moderate technical challenges.
The development of VisiPlate involves integrating advanced nanomaterials into a medical device, requiring precise engineering and validation. The team's expertise mitigates these challenges.
- Patent
-
Aspect: Strong
Summary: The company holds strong patents for its nanotechnology-enabled implant.
Avisi Technologies has secured patents for VisiPlate, providing a competitive edge and protecting its innovative technology from replication.
- Financing
-
Aspect: Medium
Summary: The company has secured moderate funding from grants and investors.
With approximately $6.3 million raised, including grants from the National Science Foundation and investments from entities like Gaingels and Good Growth Capital, the company has a solid financial foundation but may need further investment for full market entry.
- Regulatory
-
Aspect: Running FIH
Summary: The company is conducting First-In-Human (FIH) trials.
Avisi Technologies has advanced VisiPlate into FIH trials, a critical step toward regulatory approval and eventual commercialization.
Opportunity Rollup
- Odds of Success
- 3.85
- Peak Market Share
- 5.2
- Segment CAGR
- 3.2%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- Glaucoma Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.78 |
| 3 | 1.82 |
| 4 | 3.64 |
| 5 | 5.20 |
Key Takeaway
Avisi Technologies is well-positioned to address a significant clinical need with its innovative VisiPlate device, though it faces challenges in a competitive and regulated market.